Focus

12:30 a.m.: Welcome lunch and visit of the stands

1:45 p.m.: Introduction of the Congress: a word from the presidents – L. Albiges, A. Briganti

2:00 p.m.: RetroPeritoneum Session

Moderators: C. Chevreau, N. Mottet

• De-escalation of treatments: Can long-term side effects be limited?

– PET-guided strategies in seminoma – Y. Loriot

– Modified curage in NSGCTs – X. Durand

• Retroperitoneal sarcomas: What treatment in 2020? D. Tzanis

2:55 p.m.: PROSTATE Session

Moderators: A. Bossi, F. Bladou, I. Latorzeff, A. De la Taille

• Is there still a place for systematized biopsies in the era of MRI? R. Mathieu

• How to limit the risk of urinary incontinence after total prostatectomy? A. Larchet

• From localized stage to metastasis: what new therapeutic combinations? With the support of Janssen laboratory
1. What systemic treatments should be combined with local treatment? S. Supiot
2. Metastatic relapses after local treatment: how to choose between treatment targeting metastasis, systemic treatment or both? S. Chowdhury

• Surgical treatment of high-risk prostate cancer: how to manage multimodal treatment in 2020? Adjuvant – A. Bossi vs. Salvage – A. Briganti

4:30 p.m.: Coffee break and visit of the stands

4:50 p.m.: BREAKING NEWS : Integrating genomics in the management of our prostate cancer patients With the support of MSD and Astra Zaneca laboratories

• What is the role of the pathologist in therapeutic and diagnostic management? Y. Allory

• What place for targeted treatments in 2020, what tolerance data and what quality of life? G. Roubaud

5:20 p.m.: MUST READ ARTICLE OF THE YEAR

Moderator: L. Albiges
Speaker: Mr. Moschini

5:40 p.m.: European Corner, CC-AFU/YAU-EAU Joint session
Residual Disease after surgery: how to manage?

Moderators : A. Necchi, A. Briganti, N. Mottet , M. Roupret

• Prostate cancer: How to deal with a detectable PSA ? G. Gandaglia

• Muscle invasive bladder cancer – M. Moschini

• Kidney cancer – U. Capitanio

6:30 p.m.: Therapeutic advances in the management of kidney cancer and urothelial tumors in 2020 With the support of MSD laboratory

Moderator: C. Chevreau

– 1st part: Kidney cancer in 2020: from localized disease to metastatic management – I. Ouzaid, C. Thibault

– 2nd part: Bladder cancer: from NMIBC to metastatic management: what options in 2020 – E. Xylinas, Y. Loriot

8:30 p.m.: Congress Dinner

8:30 a.m.: Joint Session YAU-EAU / GETUG / CCAFU / SIU
Management of Histologic Variants in Genito Urinary Tumors – Interactive cases discussion – Interactive voting

Panel moderators: C. Sternberg, Y. Allory , MO. Timsit, U. Capitanio

• Histologic variants of muscle invasive bladder cancer: impact on treatment approaches – C. Thibault

• Type 2 papillary renal cell carcinoma: from partial surgery to systemic treatment – FX. Nouhaud

9:30 a.m.: HEALTH SPORT SESSION With the support of IPSEN laboratories

Moderator: Mr. Soulie
Speakers : J. Galfione, R. Krzentowski

10:15 a.m.: Coffee Break and visit of the stands

10:35 a.m.: Hormonosensitive prostate cancer VERSUS resistant to castration: 2 distinct diseases or 2 aspects of a continuum? With the support of ASTELLAS laboratory

Moderator: L. Albiges
Speakers: A. Briganti, D. Borchielini, S. Vincendreau

11:25 a.m.: BLADDER / UROTHELIAL SESSION

Moderators: G. Gravis, R. Gaston, J. Walz

• Perioperative chemotherapy in upper extremity tumors: In the era of POUT – C. Thibault

• Immuno competence: state of the art – Mr Ayyoub

12:00 a.m.: Lunch and visit of the stands

1:30 p.m.: BLADDER / UROTHELIAL SESSION (Continued)

• Perioperative chemotherapy: why? Who? What is it? When? C. Sternberg

• Perioperative immunotherapy: why? Who? What is it? When? A. Necchi

• Cystectomy and curage: how to improve functional results? R. Gaston

2:30 p.m.: KIDNEY SESSION With the support of BMS laboratories

Moderators: L. Albiges, K. Bensalah, S. Supiot

• News in the medical treatment of advanced kidney cancer
With the support of BMS laboratories
Moderator: U.Capitanio
1. Management of metastatic kidney cancer in 2020 – L. Mourey
2. What criteria for choosing therapeutic combinations in advanced kidney cancer? Y. Vano
3. Nephrectomy and systemic treatments – G. Pignot

• Image-guided nephrectomy: for or against? JC. Bernard, K. Bensalah

• Neo-adjuvant and adjuvant treatments for localised kidney cancers: state of the art in 2020 – U. Capitanio

• Treatment of oligo-metastatic disease: radiotherapy of metastases with or without immunotherapy – P. Graff

4:35 p.m.: Closing of the Congress

Key messages, a word from the Presidents L. Albiges, A. Briganti, and Congress 2021